BioMarker Strategies' Unattributed - III Round

BioMarker Strategies raised a round of funding on August 19, 2011.

BioMarker Strategies is a tissue-based cancer diagnostics company that is developing the SnapPath live tumor cell testing platform to improve the treatment of cancer. This ex vivo biomarker platform w…

Articles about BioMarker Strategies' Unattributed - III Round: